SpectraScience and PENTAX Medical Announce Expanded Distribution of WavSTAT4 Optical Biopsy System in Europe
10 April 2013 - 11:00AM
Business Wire
SpectraScience, Inc. (OTCQB:SCIE), a San Diego-based medical
device company and PENTAX Europe GmbH (PENTAX Medical herein after)
jointly announce that they have agreed on expanded distribution of
the WavSTAT4 Optical Biopsy System in Europe. Increased deployments
of the WavSTAT4 system is expected in the PENTAX Medical fiscal
year (April 2013 – March 2014).
SpectraScience and PENTAX Medical Expand
Distribution of WavSTAT4 Optical Biopsy System in Europe (Photo:
Business Wire)
As previously announced in June 2012, SpectraScience entered
into an exclusive five-year agreement with PENTAX Medical to
distribute its WavSTAT Optical Biopsy System for the support of
colorectal cancer screening and diagnosis. The agreement, which
includes the company's new WavSTAT4 console and the disposable
optical biopsy forceps, covers Europe as well as Turkey, Saudi
Arabia and South Africa. PENTAX Medical is a leading provider of
flexible endoscopes, which are used with the WavSTAT System during
screening for colorectal cancer.
"We are looking forward to working with PENTAX Medical to bring
this new technology to hospitals across Europe" said Michael
Oliver, SpectraScience's Chief Executive Officer. "PENTAX Medical
is the ideal partner for our sales and marketing efforts in Europe.
Their highly-regarded sales organization has the expertise to
insure we get the maximum possible exposure in the gastroenterology
community. With expanded distribution with PENTAX Medical, we
create a situation where both companies have a vested interest in
speeding the adoption of this unique technology across Europe."
Girts Cimermans, President Europe, Middle East and Africa, PENTAX
Medical states: "We believe in an opportunity for this product and
want to have a role in building its future. We are making efforts
to pave the way for WavSTAT into clinical routine."
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets light-based analysis
systems capable of determining whether tissue is normal,
pre-cancerous or cancerous without physically removing tissue from
the body. The WavSTAT Optical Biopsy System uses light to optically
diagnose tissue and provide the physician with an immediate result.
With the CE certification obtained, allowing the sales and
shipments in the European Union, the WavSTAT System is the first
commercially available product that incorporates this innovative
technology for clinical use.
About PENTAX Medical
PENTAX Medical is a division of Hoya Group. Its mission is to
improve the standard of patient care and quality of healthcare
delivery by providing the best endoscopic products and services
with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and
SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX
Medical provides endoscopic imaging devices and solutions to the
global medical community. Headquartered in Japan, PENTAX Medical
has a worldwide focus and presence with R&D, regional sales,
service, and in-country facilities around the globe. PENTAX Medical
employees represent the diverse countries where we do business,
allowing us to provide innovative solutions tailored to meet local
needs. For more information, please visit:
http://www.pentaxmedical.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130410005593/en/
SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
Von Jan 2024 bis Jan 2025